X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Sun Pharma Fact Sheet, Sun Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Sun Pharma Fact Sheet   (SUNP)

Here is the latest financial fact sheet of Sun Pharma. For more details, see the Sun Pharma quarterly results and Sun Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

SUN PHARMA Price History

Price Rs 544.0
Mkt Cap Rs m 1,309,153
Vol '000 373.5
P/E X 17.7
P/CF X 19.1
EPS (TTM) Rs 30.7
% ch % 1.0
No. of shares m 2,406.75
% ch week % 2.8
% ch 1-mth % -11.2
% ch 12-mth % -27.6
52 week H/L Rs 854.5/493.0
(As on Jun 23, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

SUN PHARMA Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
SUN PHARMA EQUITY SHARE DATA
High Rs5948486531,0741,201 
Low Rs423554493570706 
Sales per share (Unadj.) Rs77.4109.177.6132.3117.5 
Earnings per share (Unadj.) Rs25.728.815.221.919.6 
Diluted earnings per shareRs11.012.413.118.919.6 
Cash flow per share (Unadj.) Rs28.532.117.127.723.8 
Dividends per share (Unadj.) Rs4.255.001.503.001.00 
Adj. dividends per shareRs1.832.151.292.581.00 
Dividend yield (eoy) %0.80.70.30.40.1 
Book value per share (Unadj.) Rs118.2144.789.4123.7130.5 
Adj. book value per shareRs50.862.377.0106.5130.5 
Shares outstanding (eoy) m1,035.581,035.582,071.162,071.162,406.60 
Bonus/Rights/Conversions  --B1:1-- 
Price / Sales ratio x6.66.47.46.28.1 
Avg P/E ratio x19.824.337.837.548.7 
P/CF ratio (eoy) x17.921.933.429.740.1 
Price / Book Value ratio x4.34.86.46.67.3 
Dividend payout %16.617.49.913.75.1 
Avg Mkt Cap Rs m526,592725,9421,186,7751,703,0112,294,813 
No. of employees `00012.614.014.0NA14.7 
Total wages/salary Rs m11,87715,34520,74445,02647,971 
Avg. sales/employee Rs Th6,364.78,071.311,486.0NM19,169.8 
Avg. wages/employee Rs Th942.61,096.11,481.7NM3,253.0 
Avg. net profit/employee Rs Th2,108.52,130.82,243.9NM3,197.9 
SUN PHARMA INCOME DATA
Net Sales Rs m80,195112,999160,804273,920282,697 
Other income Rs m2,3002,7632,6475,4776,170 
Total revenues Rs m82,495115,761163,451279,397288,867 
Gross profit Rs m32,04348,96272,87378,66783,239 
Depreciation Rs m2,9123,3624,09211,94710,135 
Interest Rs m2824324425,7904,769 
Profit before tax Rs m31,15047,93270,98666,40774,505 
Minority Interest Rs m-3,855-4,863-7,375-9,363-11,126 
Prior Period Items Rs m000-126-19 
Extraordinary Inc (Exp) Rs m2,404-4,783-25,174-2,378-6,852 
Tax Rs m3,1328,4567,0229,1479,349 
Profit after tax Rs m26,56729,83131,41545,39447,159 
Gross profit margin %40.043.345.328.729.4 
Effective tax rate %10.117.69.913.812.5 
Net profit margin %33.126.419.516.616.7 
SUN PHARMA BALANCE SHEET DATA
Current assets Rs m102,934115,030186,865289,158308,646 
Current liabilities Rs m26,18528,41359,896161,468132,477 
Net working cap to sales %95.776.779.046.662.3 
Current ratio x3.94.03.11.82.3 
Inventory Days Days9583717683 
Debtors Days Days9578506888 
Net fixed assets Rs m32,74250,77158,242110,201133,606 
Share capital Rs m1,0361,0362,0712,0712,407 
"Free" reserves Rs m112,503136,274163,019222,763266,909 
Net worth Rs m122,358149,897185,250256,232314,042 
Long term debt Rs m1,5541,15348713,68431,167 
Total assets Rs m164,740205,827293,708487,985542,196 
Interest coverage x111.5112.1161.612.516.6 
Debt to equity ratio x0000.10.1 
Sales to assets ratio x0.50.50.50.60.5 
Return on assets %16.314.710.810.59.6 
Return on equity %21.719.917.017.715.0 
Return on capital %24.225.620.922.417.8 
Exports to sales %18.217.014.116.914.0 
Imports to sales %6.04.73.64.53.1 
Exports (fob) Rs m14,62819,23822,71346,23539,572 
Imports (cif) Rs m4,8195,3535,77912,2298,882 
Fx inflow Rs m14,64619,61523,16848,70642,171 
Fx outflow Rs m6,3697,87712,62925,56421,583 
Net fx Rs m8,27711,73910,53923,14220,588 
SUN PHARMA CASH FLOW
From Operations Rs m 22,345 33,566 39,592 56,157 67,694 
From Investments Rs m -8,627 -26,351 -23,668 -28,657 -44,549 
From Financial Activity Rs m -5,444 -6,650 5,066 -11,865 -19,243 
Net Cashflow Rs m 8,274 565 20,990 15,635 3,902 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 63.7%
Foreign collaborators 0.0%
Indian inst/Mut Fund 5.1%
FIIs 23.0%
ADR/GDR 0.0%
Free float 8.3%
Shareholders 133,026
Pledged promoter(s) holding 0.5%
 

Company Information

REGD OFF Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390 020
E-MAIL sunil.ajmera@sunpharma.com WEB www.sunpharma.com
TELEPHONE (022) 6696 9696 FAX (022) 2821 2010
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Cmpd., LBS Marg, Mumbai-78
AUDITOR Deloitte Haskins & Sells
CHM: Israel Makov COMP SEC: Sunil R. Ajmera YEAR OF INC: 1993 BSE CODE: 524715 FV (Rs): 1 DIV YIELD (%): 0.2

More Pharmaceuticals Company Fact Sheets:   BIOCON LTD  AMAR REMEDIES  TTK HEALTHCARE  DR. REDDYS LAB  ALKEM LABORATORIES  

Compare SUN PHARMA With:   BIOCON LTD  AMAR REMEDIES  TTK HEALTHCARE  DR. REDDYS LAB  ALKEM LABORATORIES  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Share Markets End the Week on a Dull Note(RoundUp)

Global financial markets ended the week on a dull note. This was on back of the Federal Reserve's release of its May 2-3 policy meeting minutes.

Views on news

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

More Views on News

Most Popular

A Pharma IPO in a Market That Loves IPOs but Hates Pharma(The 5 Minute Wrapup)

Jun 15, 2017

Tomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?

Bitcoin at $10,000?(Vivek Kaul's Diary)

Jun 14, 2017

Whether you're Venezuela or China or in India or the US...and you want to protect your wealth, you need real money. All the government has on offer is funny money.

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Walter Schloss' Investing Record(Chart Of The Day)

Jun 17, 2017

In a market full of one-hit-wonders, this investor obviously had a formula that worked. And through the think-and-thin of the market.

11 Hidden Costs Associated With Your Home Loan(Outside View)

Jun 16, 2017

Various costs associated with a home loan.

More

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUN PHARMA

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS